Details of the Drug

General Information of Drug (ID: DMMG26Z)

Drug Name
Dolasetron
Synonyms Dolasetronum; Dolasteron; Anzemet (TN); Dolasetron (INN); Dolasetron [INN:BAN]; Dolasetronum [INN-Latin]; 3-oxooctahydro-2h-2,6-methanoquinolizin-8-yl 1h-indole-3-carboxylate
Indication
Disease Entry ICD 11 Status REF
Nausea MD90 Approved [1]
Therapeutic Class
Antiemetics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 324.4
Topological Polar Surface Area (xlogp) 3.4
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption
The drug is well orally absorbed [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
75% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 180 mL/min/kg [5]
Elimination
0% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 8.1 hours [5]
Metabolism
The drug is metabolized via the hepatic [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 4.105 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.49% [5]
Vd
The volume of distribution (Vd) of drug is 5.8 L/kg [7]
Chemical Identifiers
Formula
C19H20N2O3
IUPAC Name
[(3S,7R)-10-oxo-8-azatricyclo[5.3.1.03,8]undecan-5-yl] 1H-indole-3-carboxylate
Canonical SMILES
C1[C@@H]2CC(C[C@H]3N2CC(=O)C1C3)OC(=O)C4=CNC5=CC=CC=C54
InChI
InChI=1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2/t11?,12-,13+,14?
InChIKey
UKTAZPQNNNJVKR-AKJUYKBHSA-N
Cross-matching ID
PubChem CID
3033818
ChEBI ID
CHEBI:94561
CAS Number
115956-12-2
DrugBank ID
DB00757
TTD ID
D00YLW
INTEDE ID
DR0524
ACDINA ID
D00209

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 3A receptor (HTR3A) TTPC4TU 5HT3A_HUMAN Antagonist [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Nausea
ICD Disease Classification MD90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 3A receptor (HTR3A) DTT HTR3A 6.60E-01 1.08E-02 0.04
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 8.20E-01 -1.63E-03 -1.13E-02
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 7.48E-04 3.43E-01 6.77E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.40E-01 -2.17E-02 -4.03E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dolasetron
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Dolasetron and Promethazine. Nausea/vomiting [MD90] [46]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Dolasetron and Granisetron. Nausea/vomiting [MD90] [46]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Dolasetron and Ondansetron. Nausea/vomiting [MD90] [46]
Coadministration of a Drug Treating the Disease Different from Dolasetron (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Dolasetron and Ivosidenib. Acute myeloid leukaemia [2A60] [47]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Dolasetron and Midostaurin. Acute myeloid leukaemia [2A60] [46]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Dolasetron and Idarubicin. Acute myeloid leukaemia [2A60] [46]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Dolasetron and Arn-509. Acute myeloid leukaemia [2A60] [46]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Dolasetron and Gilteritinib. Acute myeloid leukaemia [2A60] [46]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Dolasetron and Oliceridine. Acute pain [MG31] [46]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Dolasetron and Rivastigmine. Alzheimer disease [8A20] [46]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Dolasetron and Donepezil. Alzheimer disease [8A20] [46]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Dolasetron and Metronidazole. Amoebiasis [1A36] [48]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Dolasetron and Ivabradine. Angina pectoris [BA40] [49]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Dolasetron and Bepridil. Angina pectoris [BA40] [46]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Dolasetron and Dronedarone. Angina pectoris [BA40] [46]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Dolasetron and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [50]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Dolasetron and Cilostazol. Arterial occlusive disease [BD40] [46]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Dolasetron and Posaconazole. Aspergillosis [1F20] [46]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Dolasetron and Levalbuterol. Asthma [CA23] [51]
Terbutaline DMD4381 Major Increased risk of prolong QT interval by the combination of Dolasetron and Terbutaline. Asthma [CA23] [52]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Dolasetron and Pirbuterol. Asthma [CA23] [52]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Dolasetron and Salbutamol. Asthma [CA23] [53]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Dolasetron and Formoterol. Asthma [CA23] [52]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Dolasetron and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [46]
Desipramine DMT2FDC Major Additive serotonergic effects by the combination of Dolasetron and Desipramine. Attention deficit hyperactivity disorder [6A05] [46]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Dolasetron and Ofloxacin. Bacterial infection [1A00-1C4Z] [46]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Dolasetron and Clarithromycin. Bacterial infection [1A00-1C4Z] [46]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Dolasetron and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [46]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Dolasetron and Sparfloxacin. Bacterial infection [1A00-1C4Z] [54]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Dolasetron and Gemifloxacin. Bacterial infection [1A00-1C4Z] [46]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Dolasetron and Norfloxacin. Bacterial infection [1A00-1C4Z] [46]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Dolasetron and Levofloxacin. Bacterial infection [1A00-1C4Z] [46]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Dolasetron and Lomefloxacin. Bacterial infection [1A00-1C4Z] [46]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Dolasetron and Telithromycin. Bacterial infection [1A00-1C4Z] [46]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Dolasetron and Retigabine. Behcet disease [4A62] [46]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Dolasetron and Loperamide. Bowel habit change [ME05] [55]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Dolasetron and Eribulin. Breast cancer [2C60-2C6Y] [46]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Dolasetron and Lapatinib. Breast cancer [2C60-2C6Y] [46]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Dolasetron and Bosutinib. Breast cancer [2C60-2C6Y] [46]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Dolasetron and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [46]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Dolasetron and Olodaterol. Chronic obstructive pulmonary disease [CA22] [52]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Dolasetron and Vilanterol. Chronic obstructive pulmonary disease [CA22] [51]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Dolasetron and Salmeterol. Chronic obstructive pulmonary disease [CA22] [52]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Dolasetron and Indacaterol. Chronic obstructive pulmonary disease [CA22] [52]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Dolasetron and Arformoterol. Chronic obstructive pulmonary disease [CA22] [52]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Dolasetron and Dihydrocodeine. Chronic pain [MG30] [56]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Dolasetron and Levomilnacipran. Chronic pain [MG30] [46]
Isoproterenol DMK7MEY Major Increased risk of ventricular arrhythmias by the combination of Dolasetron and Isoproterenol. Conduction disorder [BC63] [52]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Dolasetron and Halothane. Corneal disease [9A76-9A78] [46]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Dolasetron and Propofol. Corneal disease [9A76-9A78] [57]
Alfentanil DMVO0UB Major Additive serotonergic effects by the combination of Dolasetron and Alfentanil. Corneal disease [9A76-9A78] [46]
Remifentanil DMZTXCH Major Additive serotonergic effects by the combination of Dolasetron and Remifentanil. Corneal disease [9A76-9A78] [46]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Dolasetron and Probucol. Coronary atherosclerosis [BA80] [46]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Dolasetron and Clofazimine. Crohn disease [DD70] [46]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Dolasetron and Mifepristone. Cushing syndrome [5A70] [46]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Dolasetron and Pasireotide. Cushing syndrome [5A70] [46]
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Dolasetron and Sertraline. Depression [6A70-6A7Z] [46]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Dolasetron and Vilazodone. Depression [6A70-6A7Z] [46]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Dolasetron and Nefazodone. Depression [6A70-6A7Z] [46]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Dolasetron and Vortioxetine. Depression [6A70-6A7Z] [46]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Dolasetron and Isocarboxazid. Depression [6A70-6A7Z] [46]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Dolasetron and Milnacipran. Depression [6A70-6A7Z] [46]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Dolasetron and Escitalopram. Depression [6A70-6A7Z] [46]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Dolasetron and Desvenlafaxine. Depression [6A70-6A7Z] [46]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Dolasetron and Phenelzine. Depression [6A70-6A7Z] [46]
Clomipramine DMINRKW Major Additive serotonergic effects by the combination of Dolasetron and Clomipramine. Depression [6A70-6A7Z] [46]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Dolasetron and Doxepin. Depression [6A70-6A7Z] [46]
Maprotiline DMPWB7T Major Additive serotonergic effects by the combination of Dolasetron and Maprotiline. Depression [6A70-6A7Z] [46]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Dolasetron and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [48]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Dolasetron and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [46]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Dolasetron and Deutetrabenazine. Dystonic disorder [8A02] [46]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Dolasetron and Ingrezza. Dystonic disorder [8A02] [46]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Dolasetron and Solifenacin. Functional bladder disorder [GC50] [46]
Ketoconazole DMPZI3Q Major Increased risk of prolong QT interval by the combination of Dolasetron and Ketoconazole. Fungal infection [1F29-1F2F] [46]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Dolasetron and Sunitinib. Gastrointestinal stromal tumour [2B5B] [46]
Rifampin DMA8J1G Minor Increased metabolism of Dolasetron caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [58]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Dolasetron and Procarbazine. Hodgkin lymphoma [2B30] [46]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Dolasetron and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [46]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Dolasetron and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [58]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Dolasetron and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [58]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Dolasetron and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [46]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Dolasetron and Polyethylene glycol. Irritable bowel syndrome [DD91] [59]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Dolasetron and Phenolphthalein. Irritable bowel syndrome [DD91] [46]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Dolasetron caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [49]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Dolasetron and Crizotinib. Lung cancer [2C25] [60]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Dolasetron and Ceritinib. Lung cancer [2C25] [46]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Dolasetron and Osimertinib. Lung cancer [2C25] [46]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Dolasetron and Selpercatinib. Lung cancer [2C25] [49]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Dolasetron and Lumefantrine. Malaria [1F40-1F45] [48]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Dolasetron and Halofantrine. Malaria [1F40-1F45] [61]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Dolasetron and Hydroxychloroquine. Malaria [1F40-1F45] [62]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Dolasetron and Primaquine. Malaria [1F40-1F45] [46]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Dolasetron and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [46]
IPI-145 DMWA24P Moderate Decreased metabolism of Dolasetron caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [63]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Dolasetron and Arsenic trioxide. Mature B-cell lymphoma [2A85] [64]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Dolasetron and Vemurafenib. Melanoma [2C30] [46]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Dolasetron and LGX818. Melanoma [2C30] [46]
Almogran DM7I64Z Major Additive serotonergic effects by the combination of Dolasetron and Almogran. Migraine [8A80] [46]
Frovatriptan DM7RE8P Major Additive serotonergic effects by the combination of Dolasetron and Frovatriptan. Migraine [8A80] [46]
Rizatriptan DMDJMA3 Major Additive serotonergic effects by the combination of Dolasetron and Rizatriptan. Migraine [8A80] [46]
Naratriptan DMO50U2 Major Additive serotonergic effects by the combination of Dolasetron and Naratriptan. Migraine [8A80] [46]
Lasmiditan DMXLVDT Major Additive serotonergic effects by the combination of Dolasetron and Lasmiditan. Migraine [8A80] [46]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Dolasetron and Panobinostat. Multiple myeloma [2A83] [65]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Dolasetron and Thalidomide. Multiple myeloma [2A83] [48]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Dolasetron and Siponimod. Multiple sclerosis [8A40] [48]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Dolasetron and Fingolimod. Multiple sclerosis [8A40] [46]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Dolasetron and Ozanimod. Multiple sclerosis [8A40] [66]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Dolasetron and Romidepsin. Mycosis fungoides [2B01] [46]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Dolasetron and Nilotinib. Myeloproliferative neoplasm [2A20] [46]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Dolasetron and Dasatinib. Myeloproliferative neoplasm [2A20] [46]
Bupropion DM5PCS7 Major Additive serotonergic effects by the combination of Dolasetron and Bupropion. Nicotine use disorder [6C4A] [46]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Dolasetron and Sibutramine. Obesity [5B80-5B81] [46]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Dolasetron and Dexfenfluramine. Obesity [5B80-5B81] [46]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Dolasetron and Levomethadyl Acetate. Opioid use disorder [6C43] [49]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Dolasetron and Lofexidine. Opioid use disorder [6C43] [46]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Dolasetron and Rucaparib. Ovarian cancer [2C73] [46]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Dolasetron and Oxymorphone. Pain [MG30-MG3Z] [56]
Levorphanol DMGS80V Moderate Additive serotonergic effects by the combination of Dolasetron and Levorphanol. Pain [MG30-MG3Z] [56]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Dolasetron and Dezocine. Pain [MG30-MG3Z] [56]
Nalbuphine DMOSQGU Moderate Additive serotonergic effects by the combination of Dolasetron and Nalbuphine. Pain [MG30-MG3Z] [56]
Buprenorphine DMPRI8G Major Increased risk of prolong QT interval by the combination of Dolasetron and Buprenorphine. Pain [MG30-MG3Z] [46]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Dolasetron and Hydrocodone. Pain [MG30-MG3Z] [56]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Dolasetron and Triclabendazole. Parasitic worm infestation [1F90] [46]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Dolasetron and Pimavanserin. Parkinsonism [8A00] [46]
Abametapir DM2RX0I Moderate Decreased metabolism of Dolasetron caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [67]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Dolasetron and Famotidine. Peptic ulcer [DA61] [48]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Dolasetron and Macimorelin. Pituitary gland disorder [5A60-5A61] [68]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Dolasetron and Lefamulin. Pneumonia [CA40] [69]
Ritodrine DM4V6RL Major Increased risk of prolong QT interval by the combination of Dolasetron and Ritodrine. Preterm labour/delivery [JB00] [52]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Dolasetron and Degarelix. Prostate cancer [2C82] [46]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Dolasetron and ABIRATERONE. Prostate cancer [2C82] [46]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Dolasetron and Relugolix. Prostate cancer [2C82] [46]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Dolasetron and Bicalutamide. Prostate cancer [2C82] [46]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Dolasetron and Levomepromazine. Psychotic disorder [6A20-6A25] [46]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Dolasetron and Gatifloxacin. Respiratory infection [CA07-CA4Z] [70]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Dolasetron and Quetiapine. Schizophrenia [6A20] [46]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Dolasetron and Mesoridazine. Schizophrenia [6A20] [46]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Dolasetron and Aripiprazole. Schizophrenia [6A20] [48]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Dolasetron and Iloperidone. Schizophrenia [6A20] [46]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Dolasetron and Paliperidone. Schizophrenia [6A20] [46]
Perphenazine DMA4MRX Major Increased risk of prolong QT interval by the combination of Dolasetron and Perphenazine. Schizophrenia [6A20] [46]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Dolasetron and Trifluoperazine. Schizophrenia [6A20] [46]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Dolasetron and Amisulpride. Schizophrenia [6A20] [71]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Dolasetron and Asenapine. Schizophrenia [6A20] [46]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Dolasetron and Pimozide. Schizophrenia [6A20] [49]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Dolasetron and Fentanyl. Sensation disturbance [MB40] [46]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Dolasetron and Vardenafil. Sexual dysfunction [HA00-HA01] [46]
Larotrectinib DM26CQR Moderate Decreased metabolism of Dolasetron caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [48]
Mitoxantrone DMM39BF Major Increased risk of prolong QT interval by the combination of Dolasetron and Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [46]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Dolasetron and LEE011. Solid tumour/cancer [2A00-2F9Z] [46]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Dolasetron and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [46]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Dolasetron and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [46]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Dolasetron and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [46]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Dolasetron and Pitolisant. Somnolence [MG42] [46]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Dolasetron and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [46]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Dolasetron caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [72]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Dolasetron and Lenvatinib. Thyroid cancer [2D10] [46]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Dolasetron and Cabozantinib. Thyroid cancer [2D10] [46]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Dolasetron and Papaverine. Tonus and reflex abnormality [MB47] [73]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Dolasetron and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [48]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Dolasetron and Procainamide. Ventricular tachyarrhythmia [BC71] [46]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Dolasetron and Propafenone. Ventricular tachyarrhythmia [BC71] [58]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Dolasetron and Flecainide. Ventricular tachyarrhythmia [BC71] [58]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Dolasetron and Amiodarone. Ventricular tachyarrhythmia [BC71] [46]
⏷ Show the Full List of 161 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Dolasetron 100 mg tablet 100 mg Oral Tablet Oral
Dolasetron 50 mg tablet 50 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
9 Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9.
10 Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy. Cancer Manag Res. 2012;4:67-73.
11 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
22 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
23 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
24 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
25 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
26 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
27 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
28 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
29 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
30 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
31 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
32 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
33 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
34 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
35 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
36 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
37 Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
38 Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
39 Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
40 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
41 Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
42 Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
43 Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
44 mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
45 Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.
46 Canadian Pharmacists Association.
47 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
48 Cerner Multum, Inc. "Australian Product Information.".
49 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
50 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
51 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
52 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
53 Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
54 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
55 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
56 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
57 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
58 Product Information. Anzemet (dolasetron). Hoechst Marion-Roussel Inc, Kansas City, MO.
59 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
60 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
61 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
62 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
63 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
64 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
65 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
66 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
67 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
68 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
69 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
70 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
71 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
72 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
73 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]